Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06271291

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

HonorHealth Research Institute, Scottsdale, Arizona, United States

Loading trial locations.

About this study

PRIMARY OBJECTIVES:

I. To develop a cohort (biobank of biospecimens and data) of subjects without pancreatic cancer who are at highrisk for pancreatic cancer due to: a strong family history, a mutation in a known pancreatic cancer predisposition gene, or fukuoka worrisome or high-risk pancreatic cysts.

II. To follow the cohort subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes.

III. To make biospecimen available to PCDC-approved projects to validate potential biomarkers for performance using nested case-control prospective designs.

OUTLINE: This is an observational study.

Participants undergo blood sample collection, complete questionnaires, have their medical records reviewed and undergo pancreatic cyst fluid collection during standard of care endoscopic ultrasounds fine needle aspiration.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS:
  • Age: 50 or older, plus at least one of the following:
  • Mutation unknown or absent:
  • 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject;
  • OR 2+ affected first degree relatives [(FDR), defined as blood related parents, siblings, or children]
  • Known pathogenic/likely pathogenic (P/LP) mutation in at least one of the following:
  • CDKN2A/p16, Peutz-Jeghers syndrome (PJS) serine/threonine kinase 11 (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1)
  • OR 1+ or second degree relative (SDR) with PDAC and a known P/LP mutation in one or more of:
  • ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53
  • HIGH-RISK OR WORRISOME PANCREATIC CYSTS:
  • 18 years of age or greater and meeting Fukuoka worrisome (FW) or Fukuoka high-risk (FHR) criteria
  • High risk stigmata:
  • Obstructive Jaundice in a patient with cystic lesion of the head of the pancreas
  • Enhancing mural nodule ≥ 5 mm
  • Main pancreatic duct ≥ 10 mm
  • Worrisome features:
  • Presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct => 6 mm
  • Cyst ≥ 3 cm
  • Enhancing mural nodule < 5 mm
  • Thickened/Enhancing cyst wall
  • Main duct size 5-9 mm
  • Pancreatitis
  • Lymphadenopathy
  • Increased CA 19-9
  • Cyst growth rate ≥ 5 mm /2 years

Exclusion criteria

  • Is unable to provide informed consent
  • Has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma)
  • Current or prior history of PDAC or total pancreatectomy
  • Is currently a prison inmate
  • Is not able to speak or read English

Treatment and study plan

Non-Interventional Study

Other

Non-interventional study

Primary outcomes

  1. Develop a biobank of biospecimens and data of subjects without pancreatic cancer who are at high risk for pancreatic cancer

    Time frame: Baseline (at enrollment)

    Assessed by the number of specimens collected for subjects at right risk for pancreatic cancer due to a strong family history, a mutation in a known pancreatic cancer predisposition gene, or Fukuoka worrisome or high-risk pancreatic cysts.

  2. Follow subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes

    Time frame: Up to study completion, as defined in description

    Participants will be followed until study completion, defined as when one or more of the following occur:

    • Subject has provided a pre-treatment biospecimen after diagnosis with pancreatic ductal adenocarcinoma (PDAC) or it has been determined that collection of a pre-treatment biospecimen sample after PDAC diagnosis is infeasible.
    • Enrollment cyst determined to not be mucinous and thus not worthy of ongoing surveillance.
    • Subject has had a complete pancreatectomy.
    • Subject has died.
    • Study funding has ended

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Trials Referral Office

CONTACT

[email protected]

855-776-0015

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Important dates

Study start
2024
Primary completion
2029
Study completion
2029
First posted
Feb 21, 2024
Registry last updated
Jun 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.